Scientists in Germany say they've been able to create a nasal vaccine that can shut down a Covid-19 infection at its source in the nose and throat. The vaccine uses a weakened form of the coronavirus and has shown promising results in hamster studies, where it achieved "sterilizing immunity" and prevented illness.
The researchers manipulated the genetic material in the virus to make it harder for cells to translate, essentially hobbling the virus so that the immune system can recognize and fight it without making the person sick. The vaccine works by boosting mucosal immunity, which is crucial for preventing the virus from entering the body through the upper airways.
The results of this study are encouraging, but more testing needs to be done before the vaccine can be used on humans. Researchers are working on phase I clinical trials with a Swiss company called RocketVax. The study began in 2021, before the Omicron variant was around, so the vaccine tested in these experiments was made with the original strain of the coronavirus.
While this vaccine shows promise, experts say caution is warranted. Other nasal vaccines are already being developed and tested, but they have had mixed results. Researchers hope that a pan-coronavirus vaccine that induces mucosal immunity could be more effective against future variants.
There are several other nasal vaccines in development, including one produced cheaply in chicken eggs and another using a live but weakened version of the virus. Results from these studies may come later this year. The German team is eagerly watching for data on these other vaccines to see if they show promise.
The researchers manipulated the genetic material in the virus to make it harder for cells to translate, essentially hobbling the virus so that the immune system can recognize and fight it without making the person sick. The vaccine works by boosting mucosal immunity, which is crucial for preventing the virus from entering the body through the upper airways.
The results of this study are encouraging, but more testing needs to be done before the vaccine can be used on humans. Researchers are working on phase I clinical trials with a Swiss company called RocketVax. The study began in 2021, before the Omicron variant was around, so the vaccine tested in these experiments was made with the original strain of the coronavirus.
While this vaccine shows promise, experts say caution is warranted. Other nasal vaccines are already being developed and tested, but they have had mixed results. Researchers hope that a pan-coronavirus vaccine that induces mucosal immunity could be more effective against future variants.
There are several other nasal vaccines in development, including one produced cheaply in chicken eggs and another using a live but weakened version of the virus. Results from these studies may come later this year. The German team is eagerly watching for data on these other vaccines to see if they show promise.